DANIEL G WELCH
CIK 1206199 · Chairman, CEO and President · last filed 2026-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$7.53M
Companies
8
Total Filings
118
Lifetime Open-Market Net
-$34.94M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GPCR | Director | 123,508 | $52.13 | $6.44M | $0 | 5 | 2026-06-18 |
| RARE | Director | 40,441 | $26.96 | $1.09M | $0 | 13 | 2026-05-18 |
| PRTA | Director | — | $9.22 | — | $0 | 4 | 2026-05-15 |
| Nuvation Bio Inc. (NUVB.WS) Delisted | Director | 659,947 | $0.01 | $3.4K | $0 | 6 | 2024-05-29 |
| Seagen Inc. (SGEN) Delisted | Director | 0 | $228.74 | $0 | -$34.84M | 31 | 2023-12-15 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Director | 8,060 | $19.00 | $153.1K | -$102.1K | 8 | 2020-06-01 |
| AveXis, Inc. (AVXS) Delisted | Director | 0 | — | — | $0 | 4 | 2018-05-15 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | Director | 0 | — | — | $0 | 3 | 2015-05-08 |
Recent Filings · Page 3 of 12
118 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-05-15 | — | Notice (144) | −1,864 | -$372.8K | EDGAR |
| 2023-05-03 | Seagen Inc. (SGEN) Delisted | Mixed | −11,371 | -$3.82M | EDGAR |
| 2023-05-02 | — | Notice (144) | −351 | -$70.2K | EDGAR |
| 2023-05-02 | — | Notice (144) | −5,835 | -$1.17M | EDGAR |
| 2023-05-02 | — | Notice (144) | −8,521 | -$1.70M | EDGAR |
| 2023-05-01 | — | Notice (144) | −295 | -$59.0K | EDGAR |
| 2023-05-01 | — | Notice (144) | −4,890 | -$978.1K | EDGAR |
| 2023-05-01 | — | Notice (144) | −7,140 | -$1.43M | EDGAR |
| 2023-04-12 | Seagen Inc. (SGEN) Delisted | — | — | $0 | EDGAR |
| 2023-04-05 | Seagen Inc. (SGEN) Delisted | Mixed | −13,475 | -$5.18M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.